Fluticasone- vs Budesonide-Based Dual Therapy for COPD
In this cohort study of new ICS-LABA users with COPD, once-daily dry powder fluticasone furoate-vilanterol inhalers were associated with slightly improved clinical outcomes compared with twice-daily metered-dose budesonide-formoterol inhalers and twice-daily dry powder fluticasone propionate-salmeterol inhalers. Further studies are needed to explore potential intraclass differences among inhalers used to treat COPD.
Authors
- Vidya L. Ambati (ORCID: https://orcid.org/0009-0002-2952-0002)
- S Wang
- William B. Feldman (ORCID: https://orcid.org/0000-0003-3467-5869)
- Aaron Seth Kesselheim (ORCID: https://orcid.org/0000-0002-8867-2666)
- Samy Suissa
- Jerry Avorn
- Sebastian Schneeweiss
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Jewish General Hospital (CA)
- Pulmonary and Allergy Associates (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2026-03-09
- DOI
- https://doi.org/10.1001/jamanetworkopen.2026.0959
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00